首页> 美国卫生研究院文献>Springer Open Choice >Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

【2h】

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

机译：曲妥珠单抗加S-1在老年HER2阳性晚期胃癌患者中的多中心II期研究（JACCRO GC-06）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundS-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. In the HERBIS-1 trial, trastuzumab combined with S-1 plus cisplatin showed promising antitumor activity in patients with HER2-positive AGC. However, cisplatin has several important drawbacks, including vomiting and renal toxicity. These disadvantages of cisplatin are prominent in elderly patients. Therefore, we conducted a prospective phase II study of trastuzumab plus S-1 without cisplatin in elderly patients with HER2-positive AGC.

机译：背景S-1加顺铂是亚洲晚期胃癌（AGC）的标准治疗方案。 ToGA试验建立了氟嘧啶加顺铂和曲妥珠单抗作为人表皮生长因子受体2（HER2）阳性AGC的标准治疗方法。在HERBIS-1试验中，曲妥珠单抗联合S-1加顺铂对HER2阳性AGC患者显示出有希望的抗肿瘤活性。但是，顺铂有几个重要的缺点，包括呕吐和肾毒性。顺铂的这些缺点在老年患者中很明显。因此，我们对患有HER2阳性AGC的老年患者进行了曲妥珠单抗加S-1（不含顺铂）的前瞻性II期研究。

著录项

期刊名称 Springer Open Choice
作者
Yutaka Kimura; Masashi Fujii; Toshiki Masuishi; Kazuhiro Nishikawa; Chikara Kunisaki; Satoshi Matsusaka; Yoshihiko Segawa; Masato Nakamura; Kinro Sasaki; Narutoshi Nagao; Yukimasa Hatachi; Yasuhiro Yuasa; Shinya Asami; Masahiro Takeuchi; Hiroshi Furukawa; Toshifusa Nakajima; Tomono Kawase; Ryohei Kawabata; Yutaka Kimura; Tetsuya Etou; Toshiki Masuishi; Hirochika Makino; Hidetaka Ono; Yusuke Izumisawa; Chikara Kunisaki; Kazuhiro Nishikawa; Junji Kawada; Satoshi Matsusaka; Ken Shimada; Yu Sunakawa; Yoshihiko Segawa; Masato Nakamura; Hitoshi Satomura; Kinro Sasaki; Narutoshi Nagao; Katsuyuki Kunieda; Akihito Tsuji; Hironaga Satake; Yukimasa Hatachi; Hisashi Ishikura; Yasuhiro Yuasa; Hiroshi Okitsu; Shinya Asami; Takahiro Ito; Kentaro Moriichi; Masazumi Takahashi; Yasutaka Takinishi; Takashi Sekikawa; Naoki Okumura; Shigemitsu Ueyama; Noriyuki Yamamura; Dai Manaka; Sachiko Oouchi; Ryuichiro Ohashi; Tomohiko Mannami; Kazuaki Tanabe; Takeshi Shiraishi;
展开▼
作者单位

展开▼
年(卷),期 -1(21),3
年度 -1
页码 421–427
总页数 7
原文格式 PDF
正文语种
中图分类外科学;
关键词
Gastric cancer Elderly patients HER2-positive S-1 Trastuzumab;

机译：胃癌;老年患者;HER2阳性;S-1;曲妥珠单抗;

相似文献

外文文献
中文文献
专利

1. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06) [J] . Kimura Yutaka, Fujii Masashi, Masuishi Toshiki, Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association . 2018,第3期

机译：单独的HERS2阳性晚期胃癌患者TRASTUZUMAB加S-1的多中心期II研究（Jaccro GC-06）
2. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06) (vol 21, pg 421, 2017) [J] . Kimura Yutaka, Fujii Masashi, Masuishi Toshiki, Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association . 2018,第3期

机译：单独的HER2阳性晚期胃癌患者曲妥珠单抗S-1的多中心期II研究（Jaccro GC-06）（Vol 21，PG 421,2017）
3. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer [J] . Takahari Daisuke, Chin Keisho, Ishizuka Naoki, Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association . 2019,第6期

机译：曲妥珠单抗与S-1加上奥沙拉铂研究化疗 - 幼稚，海绵体幼虫，HER2阳性晚期胃癌
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II multicenter open-label single-arm study [O] . Feng Wang, Tian-Shu Liu, Xiang-Lin Yuan, 2020

机译：Trastuzumab Plus Docetaxel和Capecitabine作为Her2阳性晚期胃或胃食管接线癌的一线治疗：II期多中心开放标签单臂学习
7. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06) [O] . Yutaka Kimura, Masashi Fujii, Toshiki Masuishi, 2017

机译：单独的HERS2阳性晚期胃癌患者TRASTUZUMAB加S-1的多中心期II研究（Jaccro GC-06）

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

摘要

著录项

相似文献

相关主题

期刊订阅